In a 55‑year‑old man with moderate‑risk membranous nephropathy, what is the recommended rituximab dosing schedule, and is low‑dose oral prednisone necessary or is rituximab monotherapy sufficient, with repeat dosing every six months while continuing maximal ACE‑inhibitor/ARB therapy?

Rituximab Dosing in Membranous Nephropathy

For moderate-risk membranous nephropathy, rituximab monotherapy is preferred without the need for low-dose steroids, using either 1 g IV on days 1 and 15 OR 375 mg/m² weekly for 4 weeks, with repeat dosing guided by anti-PLA2R antibody monitoring rather than fixed 6-month intervals. 1

Standard Rituximab Dosing Regimens

The KDIGO 2021 guidelines present rituximab as a first-line option for moderate-risk MN without mandating concurrent steroids 2, 1. Two dosing approaches are acceptable:

• Two-dose regimen: 1 g IV on days 1 and 15 1
• Four-dose regimen: 375 mg/m² weekly for 4 weeks 3

Both regimens achieve comparable efficacy, with overall remission rates of 62-83% at 12-24 months 4, 5.

Steroid Co-Administration: Not Required

Rituximab monotherapy is the preferred approach 1. The KDIGO guidelines explicitly show rituximab as a standalone option for moderate-risk patients, distinct from the cyclophosphamide regimen which requires alternating monthly glucocorticoids 2, 1.

Key evidence:

• The landmark RI-CYCLO trial compared rituximab monotherapy versus cyclophosphamide plus steroids, demonstrating rituximab alone achieved 62% remission at 12 months and 83% at 24 months 5
• Recent studies show rituximab monotherapy achieves 65-84% remission rates without steroids 6, 7
• Adding low-dose steroids to rituximab does not significantly improve outcomes but may increase adverse events 8, 9

Exception: Some expert centers use structured low-dose prednisone tapering (starting 0.5-1 mg/kg/day, tapered over 3-6 months) combined with modified rituximab dosing for very high-risk patients, but this is not standard practice 9.

Repeat Dosing Strategy: Antibody-Guided, Not Fixed Intervals

Do not automatically redose every 6 months. Instead, use anti-PLA2R antibody monitoring to guide retreatment 1:

Monitoring Algorithm (Check at 3 and 6 months):

• Anti-PLA2R antibodies absent or <2 RU/mL: Stop rituximab, continue observation 1
• Anti-PLA2R antibodies present but decreased to <50 RU/mL: Carefully observe, may not need additional rituximab 1
• Anti-PLA2R antibodies persistently elevated: Consider retreatment with 1-2 doses of 1 g rituximab separated by 2 weeks 1

Critical Pitfall to Avoid:

B-cell depletion alone is insufficient to judge efficacy 1. Patients may have complete B-cell depletion but persistent anti-PLA2R antibodies, indicating ongoing disease activity requiring additional treatment. Always measure anti-PLA2R antibodies, not just B-cell counts.

Maximal Antiproteinuric Therapy: Essential Foundation

All patients must receive optimized RAS inhibition (ACE inhibitors or ARBs) regardless of immunosuppressive choice 1. Non-use of RAS inhibitors is an independent risk factor for treatment failure (OR 9.1) 10.

Alternative Dosing Strategies (Emerging Evidence)

Recent research suggests lower-dose rituximab may be effective in selected patients:

• Monthly 100 mg dosing: Achieved 84% remission in patients with anti-PLA2R <150 RU/mL, with significantly lower costs 7
• 500 mg weekly × 4 weeks: Comparable efficacy to standard dosing with reduced infection risk, especially in elderly patients 11

However, these approaches are not yet incorporated into guidelines and should be reserved for patients with lower baseline anti-PLA2R titers or specific contraindications to standard dosing 6, 7.

Safety Considerations

Rituximab has a favorable safety profile compared to cyclophosphamide-steroid regimens 5:

• Serious adverse events: 19% with rituximab vs. 14% with cyclophosphamide (not statistically different) 5
• Infection risk: 53-62% overall infections, 11-12% serious infections 3
• Lower infection rates with optimized dosing strategies 11, 10

Premedication required: Antihistamine, acetaminophen, and methylprednisolone before each infusion to reduce infusion reactions 3.

Summary Algorithm for Your 55-Year-Old Moderate-Risk Patient

1. Initiate: Rituximab 1 g IV on days 1 and 15 (no oral steroids needed)
2. Continue: Maximal ACE-inhibitor/ARB therapy throughout
3. Monitor: Anti-PLA2R antibodies at months 3 and 6
4. Redose decision at 6 months:
   • If anti-PLA2R negative or <2 RU/mL → Stop, observe
   • If anti-PLA2R persistently elevated → Repeat 1 g × 2 doses
5. Do not automatically redose every 6 months without antibody guidance